OverviewSuggest Edit

PerkinElmer is a company providing products, services, and solutions for the diagnostics, life sciences, and applied markets. It operates in two segments. The Discovery and Analytical Solutions segment aims to help life sciences researchers understand diseases and develop treatments. Its products also enable scientists to detect, monitor, and manage contaminants and toxic chemicals that impact environment and food supply. The Diagnostics segment provides instruments, reagents, assay platforms, and software test and screen products for the detection of genetic disorders, from pregnancy to early childhood, as well as infectious disease testing. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including Down syndrome, hypothyroidism, muscular dystrophy, infertility, and metabolic conditions.

TypePublic
Founded1931
HQWaltham, MA, US
Websiteperkinelmer.com
Employee Ratings3.5
Overall CultureC

Latest Updates

Employees (est.) (Jan 2021)14,000(+8%)
Job Openings471
Revenue (FY, 2019)$2.9 B(+4%)
Share Price (May 2021)$141.3(+3%)
Cybersecurity ratingAMore

Key People/Management at PerkinElmer

Prahlad Singh

Prahlad Singh

Director, President and Chief Executive Officer
Joel Goldberg

Joel Goldberg

Senior Vice President, Administration, General Counsel and Secretary
Jamey Mock

Jamey Mock

Senior Vice President and Chief Financial Officer
Andrew Okun

Andrew Okun

Vice President and Chief Accounting Officer
Daniel Tereau

Daniel Tereau

Senior Vice President, Strategy and Business Development
Tajinder Vohra

Tajinder Vohra

Senior Vice President, Global Operations
Show more

PerkinElmer Office Locations

PerkinElmer has offices in Waltham, Akron, American Fork, Billerica and in 67 other locations
Waltham, MA, US (HQ)
940 Winter St
Akron, OH, US
520 S Main St #2502
American Fork, UT, US
732 E 930 S #120
Billerica, MA, US
331 Treble Cove Rd, North Billerica
Boston, MA, US
549 Albany St
Branford, CT, US
29 Business Park Dr
Show all (72)

PerkinElmer Financials and Metrics

PerkinElmer Revenue

Embed Graph
View revenue for all periods
PerkinElmer's revenue was reported to be $2.88 b in FY, 2019 which is a 3.8% increase from the previous period.
USD

Revenue (Q3, 2020)

964.0m

Gross profit (Q3, 2020)

527.4m

Gross profit margin (Q3, 2020), %

54.7%

Net income (Q3, 2020)

176.7m

EBIT (Q3, 2020)

248.0m

Market capitalization (13-May-2021)

15.4b

Closing stock price (13-May-2021)

141.3

Cash (4-Oct-2020)

258.3m

EV

17.2b
PerkinElmer's current market capitalization is $15.4 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

2.3b2.8b2.9b

Revenue growth, %

7%23%4%

Cost of goods sold

1.2b1.4b1.5b

Gross profit

1.1b1.3b1.4b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

644.0m703.4m674.3m648.7m722.5m706.9m652.4m811.7m964.0m

Cost of goods sold

351.8m363.2m342.0m340.9m374.7m364.6m344.4m364.4m436.6m

Gross profit

292.2m340.1m332.3m307.8m347.8m342.3m308.0m447.3m527.4m

Gross profit Margin, %

45%48%49%47%48%48%47%55%55%
Annual
USDFY, 2017FY, 2019FY, 2018

Cash

202.1m191.9m163.1m

Accounts Receivable

552.3m725.2m632.7m

Inventories

351.7m356.9m338.3m

Current Assets

1.2b1.4b1.2b
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

292.6m237.9m227.6m

Depreciation and Amortization

105.0m180.6m214.0m

Inventories

(17.9m)(30.2m)(9.6m)

Accounts Payable

34.3m8.9m7.4m
Quarterly
USDFY, 2017

Revenue/Employee

237.6k
Show all financial metrics

PerkinElmer Operating Metrics

FY, 2017FY, 2018FY, 2019

Sales Representatives

4 k4.8 k5.3 k

Countries (Sales Representatives)

353538

Countries (Sales and Service)

150180190

Locations

210215
Show all operating metrics

PerkinElmer Acquisitions / Subsidiaries

Company NameDateDeal Size
Oxford ImmunotecJanuary 07, 2021$591 m
Horizon DiscoveryNovember 02, 2020$383 m
Cisbio.comApril 26, 2019
Shanghai Spectrum Instruments Co. Ltd.May 23, 2018
RHS LtdFebruary 26, 2018
EUROIMMUN AGJune 19, 2017$1.3 b
Tulip DiagnosticsJanuary 09, 2017
Vanadis DiagnosticsJanuary 26, 2016
Perten InstrumentsNovember 24, 2014$266 m
Ceiba SolutionsOctober 29, 2014
Show more

PerkinElmer Revenue Breakdown

Embed Graph

PerkinElmer revenue breakdown by business segment: 39.4% from Diagnostics and 60.6% from Discovery & Analytical Solutions

PerkinElmer revenue breakdown by geographic segment: 27.3% from Europe, 33.9% from Asia and 38.8% from Americas

PerkinElmer Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

PerkinElmer Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

PerkinElmer Online and Social Media Presence

Embed Graph

PerkinElmer Company Culture

  • Overall Culture

    C

    65/100

  • CEO Rating

    A-

    75/100

  • Compensation

    B-

    67/100

  • Diversity

    C

    63/100

Learn more on Comparably

PerkinElmer News and Updates

Insights on the Metagenomic Sequencing Global Market to 2027 - Featuring BGI, Illumina and PerkinElmer Among Others

Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Metagenomic Sequencing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the global market for Metagenomic Sequencing estimated at US$1.1 Billion in the year 2020, is proje…

PerkinElmer Stock Looks Attractive At $125 Levels

The stock price of PerkinElmer Inc., a Waltham-based company focused on diagnostics, life sciences, and applied services markets, is up roughly 2x from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This compares with a 71% rise for S&P.…

RNA Sample Preparation Market Business Opportunity 2020 – Top Companies PerkinElmer, DiaSorin

The RNA sample preparation utilizes next-generation sequencing technology that enables to study RNA expression and analysis studies. Posted via Industry Today. Follow us on Twitter @IndustryToday

PerkinElmer Brings ChemDraw Software to the Cloud, Enhancing Search and Collaboration Workflows

WALTHAM, Mass. – November 10, 2020 – PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today launched its newest ChemDraw® application, ChemOffice®+ Cloud, to simplify, facilitate and accelerate chemistry communication workflows. The ChemDraw platform is the leading …

PerkinElmer to Present at Stifel Virtual Healthcare Conference

Jamey Mock , SVP and chief financial officer of PerkinElmer, will provide an update on the Company and its strategic priorities.read more

PerkinElmer Launches Solus Listeria monocytogenes ELISA Assay for Testing Across Food and Environmental Samples

This new offering will help high throughput food processors and contract labs focus on L. mono testing for food and environmental surface samples. In sync with leading industry standards, the new solution is being introduced with Performance Tested Method SM (PTM) certification from AOAC® INTERNATIO…
Show more

PerkinElmer Blogs

PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC

PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC Content Import Mon, 05/17/2021 - 02:12 PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC May 17, 2021 at 2:12 AM EDT This release …

PerkinElmer to Donate 1 Million Rapid COVID-19 Antigen Tests to Combat the Pandemic’s Second Wave in India

Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India DELHI, India – May 6, 2021 – As India faces a second wave of COVID-19, PerkinElmer Inc. , a global leader committed to innovating for a healthier world, will donate 1 million PerkinElmer

PerkinElmer to Host Virtual Investor and Analyst Day

WALTHAM, Mass. --(BUSINESS WIRE)--May 4, 2021-- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a virtual Investor and Analyst Day on Thursday, June 24, 2021 from 8:30 a.m. to 12:00 p.m. ET .

PerkinElmer Announces Financial Results for the First Quarter of 2021

Revenue of $1.308 billion ; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37 ; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings Guidance WALTHAM, Mass. --(BUSINESS WIRE)--May 4, 2021-- PerkinElmer, Inc .

PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs

Leading academic and industry cluster to help address 80% of disease-relevant human proteins currently undruggable     WALTHAM, Mass. – April, 21, 2021 PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and

PerkinElmer to Present at BofA Securities 2021 Virtual Health Care Conference

PerkinElmer to Present at BofA Securities 2021 Virtual Health Care Conference Content Import Wed, 04/21/2021 - 08:01 PerkinElmer to Present at BofA Securities 2021 Virtual Health Care Conference April 21, 2021 at 8:00 AM EDT This release is a backfill from a N…
Show more

PerkinElmer Frequently Asked Questions

  • When was PerkinElmer founded?

    PerkinElmer was founded in 1931.

  • Who are PerkinElmer key executives?

    PerkinElmer's key executives are Prahlad Singh, Joel Goldberg and Jamey Mock.

  • How many employees does PerkinElmer have?

    PerkinElmer has 14,000 employees.

  • What is PerkinElmer revenue?

    Latest PerkinElmer annual revenue is $2.9 b.

  • What is PerkinElmer revenue per employee?

    Latest PerkinElmer revenue per employee is $206 k.

  • Who are PerkinElmer competitors?

    Competitors of PerkinElmer include Tecan Group, Mettler-Toledo and Agilent.

  • Where is PerkinElmer headquarters?

    PerkinElmer headquarters is located at 940 Winter St, Waltham.

  • Where are PerkinElmer offices?

    PerkinElmer has offices in Waltham, Akron, American Fork, Billerica and in 67 other locations.

  • How many offices does PerkinElmer have?

    PerkinElmer has 72 offices.